Eli Lilly Reports Positive EMBER-3 Trial Results for Imlunestrant in Breast Cancer

Eli Lilly today announced positive results from the Phase 3 EMBER-3 trial evaluating imlunestrant in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival compared to standard endocrine therapy in patients with ESR1 mutations.